Evidence map›Paper›PMID 32110438›Full record

ArticleCurrent health sciences journal

The Importance of Dermoscopy in Early Recognition of Melanoma in Situ.

S L Ianosi, M X Calbureanu-Popescu, N G Ianosi, C V Tutunaru, C D Neagoe

Abstract readCase Reports
In one paragraph

Article in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

S L IanosiDepartment of Dermatology, Medical Center Dr. Ianosi, Craiova, Romania.
M X Calbureanu-PopescuDepartment of Applied Mechanics, University of Craiova, Craiova, Romania.
N G IanosiDepartment of Surgery, Medical Center Dr. Ianosi, Craiova, Romania.
C V TutunaruDepartment of Dermatology, University of Medicine and Pharmacy of Craiova, Romania.
C D NeagoeDepartment of Internal Medicine, Medical Center Dr. Ianosi, Craiova, Romania.
University of Medicine and Pharmacy of Craiova · ROUniversity of Craiova · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early recognition of melanoma in situ (MIS) is an ongoing challenge in dermatology. It rarely arises 'de novo', most frequently resulting due to the transformation of an atypical nevus. The diagnostic criteria for MIS are diverse dermoscopy being the most used and it has a sensitivity of 83% and a specificity of 69% in detecting melanomas. The main objective of our study was to establish the sensitivity and the specificity of each of the 7-point checklist criteria used to differentiate melanocytic nevi from in situ malignant melanoma. The study group included 200 patients, aged over 18 years, with atypical pigmentary nevi after clinical aspects that presented changes in clinical appearance (shape, color, dimensions) during the last 6 months. On each patient we used the 7-point checklist of Argenziano (C1-C7). The study was performed at the Medical Center Dr. Ianosi, in Craiova between January 2016 and September 2018 and it was used Molemax HD computerized dermatoscope. The C1÷C3 criteria are significantly relevant in establishing the diagnosis of MIS in comparison with the diagnosis of nevus, unlike the C4-C7 criterion that is not definitely relevant for confirmation of the MIS diagnosis. There are no enough specific dermoscopic criteria to differentiate MIS from atypical nevus.

Indexed as

atypical nevidermoscopyMelanoma in situ

Identifiers

PMID32110438
PMCPMC7014979
OpenAlexW3011242756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.